Shares of Eli Lilly (NYSE: LLY) sank after the drugmaker lowered its full-year profit outlook, and a potential headwind to pricing and access to its drug Zepbound emerged. The company's GLP-1 drugs ...

Over the past six months, Eli Lilly has earned significant wins over its Denmark-based rival and is still at it. Recent clinical trial results Eli Lilly released suggest that it is building a lead in ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE ... of hedge funds that have stakes in them, as of Q4 2024. The hedge fund data was sourced from Insider Monkey ...

The analyst points out that Eli Lilly’s success in this area is backed by several advantages that should help it maintain a leading position and market share in the furture. Even in Q4 2024 ...

With a market cap of $775.6 billion, Eli Lilly and Company (LLY ... Lilly’s shares jumped 3.4% on Feb. 6 after the company reported Q4 2024 adjusted EPS of $5.32 and revenue of $13.5 billion ...

ELI LILLY ($LLY) is expected to release its quarterly earnings data on Thursday, May 1st before market open, per Finnhub. Analysts are expecting revenue of ...

With Q4 behind us, let’s have a look at Eli Lilly (NYSE:LLY) and its peers. The branded pharmaceutical industry relies on a high-cost, high-reward business model, driven by substantial ...

Eli Lilly (LLY.N), opens new tab, the $815 billion maker of blockbuster weight-loss drugs Mounjaro and Zepbound, is trading at more than double the valuation multiple of Wegovy maker Novo Nordisk ...

It plans to submit orforglipron for FDA approval for obesity in Q4, and for type 2 diabetes ... On the day of Eli Lilly's earnings report, CVS Health announced that its pharmacy benefit manager ...